Clinical Trial Update: A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema. [Phase 4]

View source ↗

Summary

A Phase 4 multicenter, open-label study evaluates the efficacy and safety of once-daily Mirvaso Gel in chronic persistent vascular facial erythema; the trial ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Vascular Facial Erythema

Drugs mentioned

• Mirvaso Gel (brimonidine tartrate topical gel)

Snippet

Sponsor: Galderma Brasil Ltda. | Conditions: Chronic Persistent Vascular Facial Erythema | Phase 4 | Status: COMPLETED